- Home
- MFM vs CTNM Comparison
MFM vs CTNM Comparison
Compare MFM & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFM
- CTNM
- Stock Information
- Founded
- MFM 1986
- CTNM 2009
- Country
- MFM United States
- CTNM United States
- Employees
- MFM N/A
- CTNM N/A
- Industry
- MFM Finance Companies
- CTNM
- Sector
- MFM Finance
- CTNM
- Exchange
- MFM Nasdaq
- CTNM Nasdaq
- Market Cap
- MFM 219.5M
- CTNM 248.7M
- IPO Year
- MFM N/A
- CTNM 2024
- Fundamental
- Price
- MFM $5.38
- CTNM $11.21
- Analyst Decision
- MFM
- CTNM Strong Buy
- Analyst Count
- MFM 0
- CTNM 5
- Target Price
- MFM N/A
- CTNM $22.20
- AVG Volume (30 Days)
- MFM 108.1K
- CTNM 201.6K
- Earning Date
- MFM 01-01-0001
- CTNM 11-05-2025
- Dividend Yield
- MFM 4.08%
- CTNM N/A
- EPS Growth
- MFM N/A
- CTNM N/A
- EPS
- MFM 0.03
- CTNM N/A
- Revenue
- MFM N/A
- CTNM N/A
- Revenue This Year
- MFM N/A
- CTNM N/A
- Revenue Next Year
- MFM N/A
- CTNM N/A
- P/E Ratio
- MFM $176.67
- CTNM N/A
- Revenue Growth
- MFM N/A
- CTNM N/A
- 52 Week Low
- MFM $4.37
- CTNM $3.35
- 52 Week High
- MFM $5.48
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- MFM 61.49
- CTNM 55.51
- Support Level
- MFM $5.29
- CTNM $10.65
- Resistance Level
- MFM $5.41
- CTNM $12.14
- Average True Range (ATR)
- MFM 0.06
- CTNM 0.97
- MACD
- MFM -0.00
- CTNM -0.23
- Stochastic Oscillator
- MFM 89.42
- CTNM 32.20
About MFM MFS Municipal Income Trust
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.